Download PDF
Thromb Haemost 2022; 122(06): 870
DOI: 10.1055/a-1815-2142
Invited T&H Inisghts

Pentosan Polysulfate—A “Better Heparin” as Potential Medication for the Treatment of SARS-CoV-2 Infections?

Gerd Bendas
1   Department of Pharmacy, University of Bonn, Bonn, Germany
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding



Publication History

Received: 29 March 2022

Accepted: 29 March 2022

Accepted Manuscript online:
01 April 2022

Article published online:
17 May 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Mycroft-West CJ, Su D, Pagani I. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. Thromb Haemost 2020; 120 (12) 1700-1715
    Thieme ConnectPubMedSearch in Google Scholar
  • 2 van Haren FMP, Page C, Laffey JG. et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 2020; 24 (01) 454
    CrossrefPubMedSearch in Google Scholar
  • 3 Bertini S, Alekseeva A, Elli S. et al. Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding. Thromb Haemost 2022;122(06):
    PubMed
  • 4 Zhang F, He P, Rodrigues AL. et al. Potential anti-SARS-CoV-2 activity of pentosan polysulfate and mucopolysaccharide polysulfate. Pharmaceuticals (Basel) 2022; 15 (02) 258
    CrossrefPubMedSearch in Google Scholar